PIK3CD and CLOVES syndrome: For our ensuing studies, we focused on alpelisib as it is the most selective and least toxic PI3K inhibitor developed so far, and is currently used to treat a mosaic overactivation of PI3K class Iα in children with PROS/CLOVES syndrome.22